About | Discover Evidence-Driven Solutions Today

Our ambition is to navigate and help our clients through the “waters” of pre- and post-approval market access challenges.

GIPAM is a global health research consultancy specialized in strategic market access and real-world evidence.

With our team of dedicated, experienced, and highly skilled consultants and our network of data providers, clinicians, and HTA experts/payors, we deliver what we promise. We strongly believe in high scientific standards and full transparency in all of our studies and projects – that is our GIPAM way.

The three majority owners of GIPAM - Jason Simeone, Sabrina Müller, and Thomas Wilke - have more than 40 years of experience in strategic market access and Real-World Evidence (RWE) studies.

Jason Simeone

Managing Director & Partner

Dr. Jason Simeone is the Head of GIPAM US.
With over 15 years of experience as a pharmacoepidemiologist, Jason has extensive expertise in conducting real-world evidence (RWE) studies across the United States, EU, and other markets.
Jason is leading our US activities, offering full-service RWE support, including drug safety, comparative effectiveness, burden of illness, database feasibility, landscaping studies, and evidence synthesis.

Sabrina Müller

Managing Director & Partner

Sabrina Müller is the Managing Director of GIPAM EU.
She has more than ten years of experience in conducting and leading health economic and real-world evidence projects and worked previously for companies such as IPAM, Ingress-Health, and Cytel.
Sabrina is specialized in advanced trial & database analyses as well as in adherence/persistence & preference studies.

Thomas Wilke

Scientific Lead & Partner

Prof. Dr. Thomas Wilke is the Scientific Leader of GIPAM.
He has 20 years of experience in leading and conducting real-world evidence studies.
Thomas leads the IPAM research institute, founded Ingress-Health, and worked for 3.5 years as Global RWE Lead for Cytel.
He brings a wealth of experience with respect to a broad range of different RWE research activities and is a specialist in strategic evidence generation planning.

Learn more about our Strategic Services

Services ❯

White Papers & Publications

Whitepapers & Publications

ECA Feasibility Questionnaire: Quick Self-Evaluation

Clinical and economic benefits of seasonal COVID-19 vaccination in Germany: results from the ROUTINE COV19 Study, September 2022 to March 2024

Barriers to Medication Adherence in Chronic Dermatological Diseases: A Validation Study of the Arabic Version of the Adherence Barriers Questionnaire and a Cross-Sectional Survey

The new discount on combination drug therapies in Germany: First numbers and assessment from a payor perspective

Trends in Epidemiology and Mortality of Patients with Bladder Cancer in Germany: A Retrospective Study Using German Claims Data

Monitoring the Burden of Lung Cancer in Germany: Trends in Incidence and Survival Using ZfKD Registry Data (2020–2023)

“Too Good to Be True?” Social Desirability Bias in Age-Related Patterns of Self-Reported Medication Adherence Among Patients with Atrial Fibrillation

GIPAM’s Unique Tool for Assessing the Feasibility of an External Control Arm Study

German Oncology Databases: Options and Assessment

The Complete RWE Study Checklist

A step by step guide to navigating JCA framework

RWE Essentials - Quick RWE study checklist

See all ❯

News & Webinars

News

WEBINAR: GER RWE studies with the brand-new nationwide FDZ-G dataset

‍ ‍Register now to secure your spot !

Lunch Event: RWE-Studien mit FDZ-G-Daten: Erste Erfahrungen

GIPAM lädt Sie herzlich zu diesem Lunch-Event ein, die Teilnahme ist kostenlos. Register now to secure your spot !

Seit Oktober 2025 ist es möglich, retrospektive Kassendatenstudien mit FDZ-G-Daten durchzuführen. Die ersten von GIPAM koordinierten Studien konnten nunmehr finalisiert werden. Das GIPAM-Team konnte bei der Beantragung der Studien, der Vorbereitung der Analysealgorithmen, deren Validierung und Testung und schließlich beim Review der Ergebnisse zentrale Erkenntnisse gewinnen, die wir im Rahmen dieser exklusiven Veranstaltung mit Ihnen teilen möchten.